Search

Your search keyword '"Friboulet, A."' showing total 1,896 results

Search Constraints

Start Over You searched for: Author "Friboulet, A." Remove constraint Author: "Friboulet, A."
1,896 results on '"Friboulet, A."'

Search Results

1. Boosting Cardiac Color Doppler Frame Rates with Deep Learning

2. Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development

3. The genomic and transcriptomic landscape of metastastic urothelial cancer

4. Ultrafast Cardiac Imaging Using Deep Learning For Speckle-Tracking Echocardiography

5. Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancer

6. The genomic and transcriptomic landscape of metastastic urothelial cancer

7. Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development

8. Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients

10. Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients

11. Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancer

12. Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience

13. Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer

14. Complex Convolutional Neural Networks for Ultrafast Ultrasound Image Reconstruction from In-Phase/Quadrature Signal

17. Reconstruction for Diverging-Wave Imaging Using Deep Convolutional Neural Networks

18. Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven Non-Small-Cell-Lung-Cancer with PIK3CA/PTEN alterations

22. Valorisation agro-écologique de sédiments lacustres en contexte de revégétalisation de pelouse subalpine (Barrage du Mont Cenis, Alpes, France)

23. Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

24. Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression

25. Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

26. Simultaneous Coded Plane-Wave Imaging Using an Advanced Ultrasound Forward Model

31. Contributors

32. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology

33. Supplementary Data S1 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors

34. Supplementary Figure S2 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors

35. Supplementary Methods S1 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors

36. Supplementary Table S1 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors

37. P1.23-07 Clinical Impact of Clonal Hematopoiesis in Patients with Advanced Non-small Cell Lung Cancer: Results of the CHIC Study

38. Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case Reports

39. 80P Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)

40. Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer

41. Supplementary Figure 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

42. Supplementary Table 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

43. Supplementary Table 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

44. Figure 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

45. Figure 5 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

46. Supplementary Figure 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

47. Supplementary Figure 4 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

48. Table 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

49. Figure 4 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

50. Figure 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Catalog

Books, media, physical & digital resources